AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Mar 22, 2017.

  1. DollarChamp

    DollarChamp Member

    Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

    This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL


    Axsome (AXSM)

    Market-Cap: $83 Million
    Cash: $50.6 Million
    Price:$3.60

    Shares Out: 23 Million


    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)


    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)


    New Presentation
    http://redirect.viglink.com/?key=bb...25/254022/Axsome_Presentation_14_Mar_2017.pdf

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%


    [​IMG]
     
  2. DollarChamp

    DollarChamp Member

    Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You

    How to Prevent your Shares Holdings from being Shorted
    http://www.contracts-for-difference.com/Borrowing-lending-shares.html
     
  3. DollarChamp

    DollarChamp Member

    MarketCap $95M /Cash $50M /5x Phase 3 = Definitely one of the most undervalued Biotech you can get in USA

    Market Cap: $92 Million
    Cash: $50 Million
    Price: 4.10

    http://biopharmcatalyst.com/companies/company-pipeline-database#sort=company

    AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.

    AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.

    AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 initiation contingent upon resources.

    AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.

    AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
     
  4. DollarChamp

    DollarChamp Member

    here we go guys we are over $4 ,, this stock is what i call a once in a lifetime opp this stock should be at $20 right now not at laughable $4 .

    5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs .

    Marketcap: $90 Million
    Cash: $50 Million
    Price: $3.95

    New Presentation
    http://phx.corporate-ir.net/Externa...9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.

    AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.

    AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3


    AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.

    AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
     
  5. DollarChamp

    DollarChamp Member

    Bigger jump in share price coming once it breaks the MA(50) at $4.36 .
     
  6. DollarChamp

    DollarChamp Member

    Need to break the MA(50) at $4.24 then $5+ coming
     
  7. DollarChamp

    DollarChamp Member

  8. DollarChamp

    DollarChamp Member

  9. DollarChamp

    DollarChamp Member

    Well written article out by J.Napodano

    Should You Invest In Axsome Therapeutics? Monday, May 8, 2017
    http://www.talkmarkets.com/content/...you-invest-in-axsome-therapeutics?post=134346

    Final Thoughts

    Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA.

    I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15.
     
  10. DollarChamp

    DollarChamp Member

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) May 10, 2017

    https://www.networknewswire.com/net...y-rating-axsome-therapeutics-inc-nasdaq-axsm/

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
     
  11. DollarChamp

    DollarChamp Member

  12. DollarChamp

    DollarChamp Member

    and another buy rating out today with tgt $14

    https://thefly.com/landingPageNews....ome-Therapeutics-initiated-with-a-Buy-at-BTIG

    Axsome Therapeutics initiated with a Buy at BTIG BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.
     
  13. DollarChamp

    DollarChamp Member

Loading...

Share This Page